LNAI · Lunai Bioworks Inc.
$2.17
-0.07 (-3.13%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$81.25M
Shares
36.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Dybul | CEO | $430,000 |
| Luisa Puche | CFO | $275,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mark Dybul | CEO | $1,262,500 |
| Luisa Puche | CFO | $280,000 |
| Robert Wolfe | CFO | — |
| Eric Leire | CEO | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark Dybul | Executive Vice Chair | $1,889,100 |
| Luisa Puche | CFO | $508,791 |
| Eric Leire | CEO | $316,388 |
| Robert Wolfe | CFO | $160,314 |